Review: Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Multiple sclerosis is a chronic, demyelinating disorder of the central nervous system. It is characterised by progressive neurological disability, which is likely to occur as a result of permanent axonal damage. Such damage may be reflected by brain atrophy, which can be identified early in the course of the disease. Patients who present with an initial episode of inflammatory demyelination, commonly referred to as a clinically isolated syndrome, are at high risk of developing clinically definite multiple sclerosis, especially if their magnetic resonance imaging studies suggest the presence of multi-focal disease. Treatment with disease-modifying therapies at the initial episode of demyelination may postpone this development. In this review we present an overview of evidence supporting early treatment initiation. We focus on three large placebo-controlled trials of interferon beta therapy: Controlled High-Risk Avonex® Multiple Sclerosis Prevention Study, Early Treatment of Multiple Sclerosis and Betaferon ® in Newly Emerging Multiple Sclerosis for Initial Treatment. Results from these early treatment studies are presented, and the impact of using interferon beta treatment in the early stages of disease is discussed with the aim of considering optimal therapeutic strategies to improve long-term patient outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H., Kappos, L., Lublin, F. D., Metz, L. M., McFarland, H. F., O'Connor, P. W., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20703 · Cited by 5,017 · cited 6×
“diagnostic scheme.44,45 These criteria provide neurologists with a system for MS diagnosis (based heavily on MRI findings) for a range of clinical presentations, including CIS, RRMS and primary progressive MS.44 A diagnosis of MS is now made when dissemination of disease both in time and in space can be demonstrated e…”
BackgroundMethodInfluentialAxonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Axonal damage in acute multiple sclerosis lesions
Ferguson, B. (1997) · Brain · doi:10.1093/brain/120.3.393 · Cited by 1,532
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.1.133 · Cited by 1,452
Schumacher, G. A., Beebe, G., Kibler, R. F., Kurland, L. T., Kurtzke, J. F., McDowell, F., Nagler, B., Sibley, W. A., Tourtellotte, W. W., & Willmon, T. L. (1965) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1965.tb20235.x · Cited by 1,438 · cited 1×
“According to these criteria, a positive diagnosis of MS relied on clinical evidence of two or more CNS lesions, accompanied by distinct attacks over time that could not be explained by other pathologies.(49) In 1983, the International Panel of Poser and colleagues incorporated several newly developed laboratory, elect…”
BackgroundBarkhof, F. (1997) · Brain · doi:10.1093/brain/120.11.2059 · Cited by 1,251 · cited 1×
“Indeed, in studies reporting improvements in the sensitivity of the new diagnostic criteria, these improvements have all resulted exclusively from the new MRI criteria for dissemination in time (not considered by the Poser panel) and not from the new MRI criteria for dissemination in space.(43,52) This controversy has…”
BackgroundKappos, L. (1998) · The Lancet · doi:10.1016/s0140-6736(98)10039-9 · Cited by 936
Acute axonal injury in multiple sclerosis: Correlation with demyelination and inflammation
Bitsch, A. (2000) · Brain · doi:10.1093/brain/123.6.1174 · Cited by 898 · cited 1×
“In later stages of plaque evolution, inflammation decreases and axon destruction seems to be associated with the activation of macrophages/microglia.(27,28) Owing to redundancy within CNS pathways, axonal loss may not initially produce permanent symptoms and signs.”
BackgroundA longitudinal study of abnormalities on MRI and disability from multiple sclerosis
Brex, P. A., Ciccarelli, O., O'Riordan, J. I., Sailer, M., Thompson, A. J., & Miller, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011341 · Cited by 861 · cited 1×
“Similarly, in a study of 71 patients followed for 14 years after CIS, patients with greater numbers and volumes of lesions on baseline MRI had worse clinical outcomes.(34) Thus, the EDSS score at 14 years correlated with the increase in lesion volume over the first 5 years of follow-up (r1⁄4 0.”
ResultInterferon beta-1b in secondary progressive MS: Results from a 3-year controlled study
The North American Study Group on Interferon beta-1b in Secondary Progressive MS (2004) · Neurology · doi:10.1212/01.wnl.0000146958.77317.3e · Cited by 423
Cited by
on behalf of the MAGNIMS study group, Rovira, À., Wattjes, M. P., Tintoré, M., Tur, C., Yousry, T. A., Sormani, M. P., De Stefano, N., Filippi, M., Auger, C., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.106 · Cited by 423
Immunomodulatory therapies delay disease progression in multiple sclerosis
Bergamaschi, R., Quaglini, S., Tavazzi, E., Amato, M. P., Paolicelli, D., Zipoli, V., Romani, A., Tortorella, C., Portaccio, E., D’Onghia, M., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458512445941 · Cited by 71
The Novo Group, Fernández, O., Fernández, V., Arbizu, T., Izquierdo, G., Bosca, I., Arroyo, R., García Merino, J. A., & de Ramón, E. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5560-1 · Cited by 69
Metadata
- Authors
- Goodin, D., & Bates, D.
- Venue
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Published
- 2009-09-08
- Volume
- 15
- Issue
- 10
- Pages
- 1175-1182
- ISSN
- 1352-4585 (ISSN-L)
- 1477-0970
- OpenAlex
- W2111588724
- Cited by
- 84
- References
- 10
- FWCI
- 5.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.